(Q33359944)

26 July 2017

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients (English)

1 reference

26 July 2017

phase II clinical trial

0 references

0 references

1 reference

Antonio Silvani

1

1 reference

26 July 2017

Marica Eoli

2

1 reference

26 July 2017

Andrea Salmaggi

3

1 reference

26 July 2017

Elena Lamperti

4

1 reference

26 July 2017

Elio Maccagnano

5

1 reference

26 July 2017

Giovanni Broggi

6

1 reference

26 July 2017

Amerigo Boiardi

7

1 reference

26 July 2017

1 January 2004

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

66

1 reference

26 July 2017

1-2

1 reference

26 July 2017

203-208

1 reference

https://scigraph.springernature.com/pub.10.1023/b:neon.0000013479.64348.69

26 July 2017

0 references

cites work

Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma

1 reference

12 December 2020

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

12 December 2020

Temozolomide for recurrent high-grade glioma

1 reference

12 December 2020

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

1 reference

12 December 2020

Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.

1 reference

12 December 2020

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies

1 reference

12 December 2020

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

1 reference

12 December 2020

Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure

1 reference

12 December 2020

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study

1 reference

12 December 2020

Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients

1 reference

12 December 2020

Clinical relevance of MGMT in the treatment of cancer

1 reference

12 December 2020

Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.

1 reference

12 December 2020

Temozolomide as second-line chemotherapy for relapsed gliomas.

1 reference

12 December 2020

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

1 reference

12 December 2020

A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme

1 reference

12 December 2020

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Current and future developments in the use of temozolomide for the treatment of brain tumours

1 reference

12 December 2020

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

1 reference

12 December 2020

Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy.

1 reference

12 December 2020

1 reference

12 December 2020

Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Recurrent malignant glioma in adults.

1 reference

12 December 2020

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

12 December 2020

Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study

1 reference

12 December 2020

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma

1 reference

12 December 2020

10.1023/B:NEON.0000013479.64348.69

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference